deucrictibant

AssetAlso PHA-022121, PHA-121, PHVS-719

Blocks bradykinin B2 receptors to relieve bradykinin-mediated angioedema attacks.

Stage
Phase 3
Modality
Small molecule
Target
BDKRB2
1
Indication
0
Trials
1
Developer

Indications

1

In the full profile

  • Targets and what it contains1
  • Owner and partners1
  • Evidence for its targets1
  • Signals1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets